Daiichi Sankyo (OTCMKTS:DSNKY) Issues Earnings Results

Daiichi Sankyo (OTCMKTS:DSNKY) issued its earnings results on Monday. The company reported $0.15 earnings per share for the quarter, Zacks reports. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%. Daiichi Sankyo updated its FY 2026 guidance to 0.910-0.910 EPS.

Daiichi Sankyo Trading Up 3.3%

DSNKY traded up $0.55 during midday trading on Monday, hitting $17.06. 256,197 shares of the company were exchanged, compared to its average volume of 445,710. The firm has a market capitalization of $32.31 billion, a P/E ratio of 15.65, a P/E/G ratio of 0.85 and a beta of -0.25. The firm’s 50 day moving average price is $17.94 and its 200-day moving average price is $20.47. Daiichi Sankyo has a 1-year low of $15.56 and a 1-year high of $28.21. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.